We are live on ! Find out more
PI

PGGM Investments Portfolio holdings

AUM $5.7B
1-Year Est. Return 17.05%
This Fund
S&P 500
This Quarter Est. Return
+11.48%
1 Year Est. Return
+17.05%
3 Year Est. Return
+53.14%
5 Year Est. Return
10 Year Est. Return
AUM
$21.6B
AUM Growth
+$2.47B
Cap. Flow
+$454M
Cap. Flow %
2.1%
Top 10 Hldgs %
24.24%
Holding
364
New
117
Increased
95
Reduced
131
Closed
8

Top Sells

Rank Stock Value
1
EQR icon
Equity Residential
EQR
+$279M
2
EXR icon
Extra Space Storage
EXR
+$159M
3
SLG icon
SL Green Realty
SLG
+$127M
4
PFE icon
Pfizer
PFE
+$107M
5
CMCSA icon
Comcast
CMCSA
+$95.6M

Sector Composition

Rank Sector Weight
1 Real Estate 43.57%
2 Technology 14.66%
3 Healthcare 9.78%
4 Industrials 7.27%
5 Consumer Discretionary 5.84%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
AVY icon
176
Avery Dennison
AVY
$13.5B
$29.8M 0.14%
192,118
+47,258
+33% +$6.84M
HSIC icon
177
Henry Schein
HSIC
$9.82B
$29M 0.13%
433,282
+215
+0% +$13.9K
BNY
178
Bank of New York Mellon
BNY
$108B
$28.8M 0.13%
679,439
-611,923
-47% -$23.5M
BRO icon
179
Brown & Brown
BRO
$24B
$28.8M 0.13%
607,330
+37,810
+7% +$1.74M
JBHT icon
180
JB Hunt Transport Services
JBHT
$25B
$28.7M 0.13%
209,869
+557
+0.3% +$73.8K
BIIB icon
181
Biogen
BIIB
$30.6B
$28.6M 0.13%
116,754
-80,309
-41% -$20.7M
KSU
182
DELISTED
Kansas City Southern
KSU
$28M 0.13%
137,201
+767
+0.6% +$144K
PGR icon
183
Progressive
PGR
$124B
$28M 0.13%
+282,776
New +$26.8M
ALXN
184
DELISTED
Alexion Pharmaceuticals
ALXN
$27.9M 0.13%
178,855
-247,308
-58% -$31.8M
C icon
185
Citigroup
C
$227B
$27.7M 0.13%
448,988
-310,823
-41% -$15.8M
MET icon
186
MetLife
MET
$61.7B
$27.5M 0.13%
585,199
-500,685
-46% -$21.7M
RHI icon
187
Robert Half
RHI
$4.37B
$27.1M 0.13%
433,804
+1,152
+0.3% +$68.7K
JAZZ icon
188
Jazz Pharmaceuticals
JAZZ
$16.7B
$26.6M 0.12%
161,388
-29,899
-16% -$4.45M
MAA icon
189
Mid-America Apartment Communities
MAA
$15.4B
$26.5M 0.12%
209,335
+555
+0.3% +$68.5K
CAH icon
190
Cardinal Health
CAH
$55.5B
$26.3M 0.12%
490,120
-155,712
-24% -$8.08M
CPRT icon
191
Copart
CPRT
$27.4B
$25.9M 0.12%
+813,452
New +$23.7M
GILD icon
192
Gilead Sciences
GILD
$165B
$24.8M 0.11%
425,991
-1,244,229
-74% -$75.1M
SEE
193
DELISTED
Sealed Air
SEE
$24.6M 0.11%
536,610
CDW icon
194
CDW
CDW
$17.1B
$24.5M 0.11%
185,587
+20,796
+13% +$2.72M
PFE icon
195
Pfizer
PFE
$154B
$24.3M 0.11%
659,983
-2,925,324
-82% -$107M
GL icon
196
Globe Life
GL
$14.2B
$24.2M 0.11%
254,353
+37
+0% +$3.29K
JEF icon
197
Jefferies Financial Group
JEF
$12.8B
$24.1M 0.11%
1,025,401
-13,440
-1% -$282K
ESS icon
198
Essex Property Trust
ESS
$18.2B
$23.6M 0.11%
99,379
-315,897
-76% -$72.9M
CHKP icon
199
Check Point Software Technologies
CHKP
$13.4B
$23.4M 0.11%
175,836
-150,403
-46% -$18.4M
HIG icon
200
Hartford Financial Services
HIG
$38.7B
$23.2M 0.11%
474,149
-235,465
-33% -$10.2M

Similar funds

PGGM Investments's Q4 2020 Portfolio in Review

As of Q4 2020, PGGM Investments held 364 positions worth $21.6B, up 13% from $19.1B the previous quarter. Its ten largest holdings account for 24% of the portfolio.

PGGM Investments's Q4 2020 filing shows 117 new, 95 increased, 131 reduced and 8 closed positions. Its largest new stake was Amazon: 1,446,080 shares worth $235M. The largest sale was Equity Residential, an estimated $279M.

By sector, the portfolio is most concentrated in Real Estate at 44% of assets, down from 45% a quarter earlier, followed by Technology and Healthcare.

  • PGGM Investments's largest Q4 2020 buy was Amazon: 1,446,080 shares worth $235M.
  • PGGM Investments added most to Apple in Q4 2020, an estimated $249M increase.
  • PGGM Investments's biggest Q4 2020 reduction was Equity Residential, cutting an estimated $279M.
  • PGGM Investments fully exited Vertex Pharmaceuticals in Q4 2020, selling an estimated $74.7M.
  • PGGM Investments's ten largest holdings make up 24% of its $21.6B portfolio in Q4 2020.
  • PGGM Investments opened 117 new positions and closed 8 in Q4 2020.
  • PGGM Investments's portfolio value rose 13% quarter-over-quarter to $21.6B.

Based on PGGM Investments's 13F filing for Q4 2020, filed 28 Jan 2021.